

## Research Article

# Insulin resistance in sub clinical hypothyroidism

Shyam Rameshwar Adhau<sup>1,\*</sup>, Sunita Girish<sup>2</sup>, Gaurav Shashikant Kansara<sup>3</sup>

<sup>1</sup>Assistant Professor, Department of Biochemistry, S.K.N.M.C & G.H., Narhe, Pune, Maharashtra, India

<sup>2</sup>Assistant Professor, Department of Biochemistry, B.J.G.M.C, Pune, Maharashtra, India

<sup>3</sup>Assistant Professor, Department of Biochemistry, Dr. R.N.C.M.M.C & G.H, Juhu Vile Parle (W), Mumbai Maharashtra, India

**Received:** 09 April 2015

**Accepted:** 07 May 2015

### \*Correspondence:

Dr. Shyam Rameshwar Adhau,

E-mail: drshyamadhau@gmail.com

**Copyright:** © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

### ABSTRACT

**Background:** Insulin resistance (IR) is an established risk factor for cardiovascular diseases. It is an underlying phenomenon in pathogenesis of type 2 Diabetes mellitus. Recent literature proves the development of insulin resistance in Overt hypothyroidism (OH), but there is controversy as to whether this association is also present in sub clinical hypothyroidism (SCH).

**Aims:** Present study was designed to explore the presence IR in SCH.

**Settings & design:** The study included 60 hypothyroidism patients and 30 age and sex matched euthyroid controls. Hypothyroidism patients were grouped as SCH (n=30) and OH (n=30).

**Methods:** We examined total cholesterol levels, fasting blood glucose, fasting serum insulin levels and Insulin resistance (calculated by using HOMA-IR software).

**Statistical analysis:** All statistical data was analysed by ANOVA using the Graph Pad Prism software, Version 5.01.

**Results:** HOMA-IR values showed highly significant association between controls and SCH. TSH levels were positively correlated with insulin and HOMA IR in patients with SCH.

**Conclusions:** Therefore, it will be good practice to screen people & Type 2 DM patients for presence of SCH, so that early detection and prompt intervention can prevent or prolong the appearance of various fatal complications associated with IR & help in managing diabetes holistically.

**Keywords:** Insulin resistance, Subclinical Hypothyroidism, HOMA-IR

### INTRODUCTION

Insulin resistance leads to multi organ damage through the medium of dyslipidemia and atherosclerosis. It has strong association with increase in cardiovascular morbidity & mortality. Also, it is the underline cause for complications occurring in type 2 DM. There are multiple clinical states which lead to development of insulin resistance. In this study we are focusing on effect of hypothyroidism on development of IR.

Based on severity of clinical signs & symptoms & Thyroid function test, hypothyroidism is classified as Overt & Subclinical. SCH is defined as the clinical state

where patient has high TSH values but normal T<sub>3</sub> & T<sub>4</sub> levels in serum as compared to normal reference levels. These patients have very few or no clinical signs and symptoms. While, in OH distinct signs and symptoms are present along with high TSH but low T<sub>3</sub> & low T<sub>4</sub> levels in serum. Prevalence of subclinical hypothyroidism is 6-8% in women (10% over the age 60) and 3% in men. Annual risk of developing overt hypothyroidism is about 4% when subclinical hypothyroidism is associated with positive TPO antibodies.<sup>1</sup>

Several studies have shown an association between insulin resistance and hypothyroidism for OH, but there is lot of controversy regarding whether this association is also

present in sub clinical hypothyroidism.<sup>2, 3</sup> This study is being carried out to find whether an association exists between insulin resistance and subclinical hypothyroidism.

**METHODS**

This study was carried out in the Department of Biochemistry in collaboration with Department of Medicine. The study protocol was approved by the Institutional Ethical Committee.

**Study design**

A total number of 90 subjects above the age of 15 years participated in the present study. Detailed medical history and relevant clinical examination data and written consent were obtained from all subjects after explaining the study procedure. 60 clinically diagnosed patients of hypothyroidism were selected as cases. These were selected from patients attending outpatient department of internal medicine, endocrine OPD as well as patients admitted in medicine & surgery wards. These subjects were divided into 2 groups as, Overt hypothyroidism (OH) (n=30) & Subclinical Hypothyroidism (SCH) subjects (n=30). 30 age and sex matched euthyroid subjects with TFT's in normal range were enrolled in present study as control group.

**Selection of study subjects**

Those who had not given consent, patients suffering from diabetes mellitus, polycystic ovarian diseases, obesity, tuberculosis, other systemic illness, liver disorders, renal disorders, congestive cardiac failure, patients on oral contraceptive pills, statins and other medications that alter thyroid functions tests were excluded from the study. Alcoholics, chronic smokers & patients already on treatment for hypothyroidism were also excluded from the study.

**Collection of blood sample**

About 4-5 ml of fasting blood samples were collected from cubital vein in a plain vacutainer for TFT, fasting serum insulin levels and total cholesterol estimation. About 1 ml. blood sample was collected from cubital vein in fluoride bulb for fasting plasma glucose estimation.

**Facilities and Equipment**

All the required facilities and equipment were available in the department of biochemistry. The study did not involve any harm to the any patient involved.

**METHODS**

Estimation of Serum TSH, T<sub>3</sub>, T<sub>4</sub> & insulin was done by Sandwich ELISA method using kit by LDN diagnostika.<sup>4-7</sup> ELISA reader and washer (Erba Lisa Scan 2) were used for measurement. Fasting Glucose was measured by

GOD-POD kit method & Total cholesterol by CHOD-PAP kit method on Auto analyzer (ERBA XL—640).<sup>8-11</sup> Insulin Resistance was calculated by using values of fasting serum insulin level & fasting plasma glucose level in Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) calculator developed by diabetes trials unit, endocrinology dept. university of Oxford.<sup>12</sup>

**Statistical analysis**

All the calculations were done using Microsoft Office Excel 2010 and statistical analysis was done using the Graph Pad Prism software, Version 5.01. All statistical data was analysed by ANOVA (one way analysis of variance) test with Bonferroni as post test. P-value less than 0.05 (P < 0.05) was considered to be statistically significant (S). P-value of less than 0.001 (P < 0.001) was considered to be statistically highly significant (HS). P-value more than 0.05 (P > 0.05) was considered to be statistically non-significant (NS).

**RESULTS**

Table 1 shows values of various biochemical parameters in different groups. Comparison is done between control & SCH (\$), Control & OH (\*), OH & SCH (#). Results which are statistically significant with P < 0.05 are denoted by various signs (\$, \*, #) in the table. In present study HOMA-IR is highly significantly elevated in OH as compared to control (2.2 ± 0.91, 0.76 ± 0.36, P value <0.001), highly significantly elevated in SCH as compared to control (1.7 ± 0.71, 0.76 ± 0.36, P value <0.001) & it's significantly elevated in OH as compared to SCH (2.2 ± 0.91, 1.7 ± 0.71, P value <0.05). Figure 1 shows the above mentioned finding.

**Table 1: Biochemical characteristics of various groups.**

Parameters	Control	SCH	OH
Age (Years)	34.1 ± 9.4	33.6 ± 11.3	36 ± 9.9
Serum TSH (µIU/ml)	3.1 ± 1.32	12.3 ± 5.2\$	18.4 ± 6.4*#
Serum T <sub>3</sub> (ng/dL)	111 ± 32	108 ± 31	58 ± 11*#
Serum T <sub>4</sub> (µg/dL)	8.8 ± 1.6	7.7 ± 2.2	3.1 ± 1.5*#
Serum Cholesterol	134 ± 14	176 ± 47\$	222 ± 53*#
Fasting Plasma Glucose	87 ± 8.7	101 ± 11\$	93 ± 12#
Fasting Serum Insulin (µIU/ml)	5.9 ± 2.7	13 ± 5.8\$	17 ± 7.1*#
HOMA-IR	0.76 ± 0.36	1.7 ± 0.71\$	2.2 ± 0.91*#

\$ control vs SCH; \* control vs OH; # OH vs SCH

Table 2 show correlation between TSH, HOMA- IR, Insulin & TC. Our study showed that TSH levels were positively correlated with insulin and HOMA IR in

patients with SCH (Figure 2) ( $r=0.693$ ,  $P<0.001$ ;  $r=0.712$ ,  $P<0.001$  respectively). Also, values of HOMA IR were positively correlate with TC ( $r=0.560$  and  $P<0.05$ ). The serum insulin levels were significantly correlated with total cholesterol ( $r=0.553$ ,  $P<0.05$ ). This indicates that insulin resistance is present not only in overt hypothyroidism but also is significantly present in sub clinical hypothyroidism patients. It also indicates that levels of insulin resistance directly correlate with level of TSH and cholesterol.




Figure 1: HOMA- IR In different study groups.

Table 2: Correlation between different parameters in SCH.

Parameter	Coefficient of correlation	P value
TSH vs. HOMA-IR	0.712	<0.001
TSH vs. Insulin	0.693	<0.001
TSH vs. TC	0.602	<0.001
HOMA-IR vs. TC	0.560	<0.05
Insulin vs. TC	0.553	<0.05




Figure 2: Linear Regression analysis between TSH & HOMA-IR.

## DISCUSSION

Hypothyroidism is a clinical state resulting from a deficiency of thyroid hormones, which leads to generalized slowing down of metabolic processes. Thyroid disease is much more prevalent in women than men. Classic symptoms of hypothyroidism are tiredness, weakness, dry skin, feeling cold, hair loss, difficulty concentrating and poor memory, constipation & weight gain with poor appetite. It is caused by a complex interaction of genetic, environmental, immunologic and lifestyle factors. The condition can be diagnosed by measuring the thyroid stimulating hormone (TSH) concentration in serum, which should be above the reference range of 0.4 -4 µIU/ml. Further, serum T<sub>4</sub> may or may not be decreased; these thyroid disorders are known as overt (OH) and sub-clinical hypothyroidism (SCH), respectively. SCH represents a condition of mild to moderate thyroid failure characterized by normal serum levels of thyroid hormones with mildly elevated serum TSH concentrations.<sup>13,14</sup> The prevalence of SCH has been reported to be between 4 and 10% of adult population samples.<sup>15-18</sup>

Nowadays, tremendous interest has been raised in the influence of thyroid hormone action on insulin levels. Confusing data are available on how insulin levels change in thyroid dysfunction. The development of insulin resistance leads to many of the metabolic abnormalities. Hypothyroidism can increase the risk of cardiovascular disease, infertility and osteoporosis. Although overt hypothyroidism is associated with insulin resistance, there is little information available on insulin action in sub clinical hypothyroidism. Insulin resistance is underline pathology of type 2 diabetes mellitus & is relatively frequently found in mild thyroid dysfunction with increased risk of dyslipidemia.<sup>19</sup> In the present study, we have explored the possible linkage among TSH, insulin resistance and serum concentrations of total cholesterol in sub clinical hypothyroidism patients. Based on serum TSH, T<sub>3</sub> & T<sub>4</sub> patients were classified into 3 groups as OH, SCH & Controls. In this study total cholesterol levels are highly significantly elevated in OH as compared to Control and SCH, and highly significantly elevated in SCH as compared to control (P value <0.001) (Table 1). The serum TSH levels positively correlate with total cholesterol levels in SCH subjects ( $r=0.602$ ,  $P <0.001$ ). The serum insulin levels also correlate significantly with total cholesterol ( $r=0.553$ ,  $P<0.05$ ) in SCH subjects (Table 2). This indicates that along with OH, patients of SCH also develop hypercholesterolemia.

### Insulin resistance in Control, SCH & OH groups

Thyroid hormones exert profound effects in the regulation of glucose homeostasis. These effects include modifications of circulating insulin levels, counter-regulatory hormones, intestinal absorption, hepatic production and uptake of glucose by peripheral tissue (fat

and muscle). All these changes produce insulin resistance which is the culprit for many complications mainly cardiovascular.

In present study HOMA-IR is highly significantly elevated in OH as compared to control ( $2.2 \pm 0.91$ ,  $0.76 \pm 0.36$ , P value  $<0.001$ ), highly significantly elevated in SCH as compared to control ( $1.7 \pm 0.71$ ,  $0.76 \pm 0.36$ , P value  $<0.001$ ) & it's significantly elevated in OH as compared to SCH ( $2.2 \pm 0.91$ ,  $1.7 \pm 0.71$ , P value  $<0.05$ ) (Table 1) (Figure 1).

Our study showed that TSH levels were positively correlated with insulin and HOMA IR in patients with SCH ( $r=0.693$ ,  $P<0.001$ ;  $r=0.712$ ,  $P<0.001$  respectively). Also, values of HOMA IR were positively correlate with TC ( $r=0.560$  and  $P<0.05$ ). The serum insulin levels were significantly correlated with total cholesterol ( $r=0.553$ ,  $P<0.05$ ) (Table 2) (Figure 2). This indicates that insulin resistance is present not only in overt hypothyroidism but also it is significantly present in sub clinical hypothyroidism patients. It also indicates that levels of insulin resistance directly correlate with level of TSH and cholesterol. Dessein PH et al (2004), Annemieke et al (2007), Owecki et al (2008), Eirini Maratou et al(2009), Amati F et al (2009) & Singh B M et al (2010) reported similar results which are in good agreement with our findings.<sup>16,17,20-23</sup> On the contrary, Bakker et al (2001), Tuzcu A et al (2005), M. Owecki et al (2006) & Al Sayed A et al (2006) found no significant correlation between insulin resistance and SCH.<sup>15,24-26</sup>

Presence of insulin resistance in SCH and OH can be explained by the various studies & hypothesis.

It has long been known that thyroid hormones act differently on liver, skeletal muscle and adipose tissue – the main targets of insulin action. Thyroid hormones up-regulate the expression of genes for GLUT-4 and phosphoglycerate kinase, involved in glucose transport and glycolysis respectively, thus acting synergistically with insulin in facilitating glucose disposal and utilization in peripheral tissues.<sup>27,28</sup> In patients with hypothyroidism, because of altered metabolism of lipid and insulin, binding of insulin to insulin receptor decreases.<sup>29</sup> Impaired translocation of GLUT 4 glucose transporters on plasma membrane occurs, resulting in decreased glucose uptake in muscles and adipose tissue.<sup>21</sup> The recent identification of a gene regulated by thyroid hormones in cultured human fibroblasts,<sup>30</sup> the transcription factor HIF-1a, responsible for elevated expression of glycolytic enzymes and glucose transporters, is an example that the field of thyroid diabetes is still open to new discoveries.

Decreased glucose disposal (as compared with euthyroid subjects) has been proved in hypothyroid patients by different methods including clamp studies,<sup>31</sup> the arteriovenous difference technique in the anterior abdominal subcutaneous adipose tissue and forearm

muscles after the consumption of a mixed meal,<sup>32</sup> the insulin tolerance test<sup>33</sup> and following intravenous or oral administration of glucose.

Apart from our study, Patricia Wu et al (2000), Duntas et al (2002), Serter et al (2004) & A Squizzato et al (2005) found that there is hypercholesterolemia & dyslipidemia in hypothyroidism patients.<sup>13,34-36</sup> It was postulated that elevated total cholesterol levels and dyslipidemia may act as one of the main culprits for development of insulin resistance in hypothyroidism. Mechanism of fatty acid induced insulin resistance is well studied by Randle et al and Gerald et al.<sup>37,38</sup> Still, there is scarcity of data available on cellular mechanisms of insulin resistance due to dyslipidemia. Further studies are required to find out the molecular and genetic basis of hypercholesterolemia and more precisely dyslipidemia induced insulin resistance in hypothyroidism patients.

Despite some limitations, the associations we found were highly significant and consistent with other studies addressing the above mentioned associations.

We believe that the results of our present work combined with previous studies provide compelling evidence of presence of significant insulin resistance in SCH patients. These findings may have important clinical relevance.

Hence, it will be good practice to screen people for presence of SCH and insulin resistance, so that early detection and prompt intervention can prevent or prolong the appearance of various fatal complications associated with insulin resistance. Also, along with diabetes treatment, if we check and treat hypothyroidism even in subclinical stage then it will take care of its contribution to total insulin resistance.

## ACKNOWLEDGMENTS

The authors would like to thank the department of Biochemistry & dept. of Medicine, B.J. Govt. Medical college & Sassoon General Hospital, Pune, Maharashtra, India, for their help and support for this work. None of the listed authors has any professional and/or financial affiliations that may be perceived to have biased this presentation.

*Funding: No funding sources*

*Conflict of interest: None declared*

*Ethical approval: The study protocol was approved by the Institutional Ethical Committee*

## REFERENCES

1. J. Larry Jameson, Antony P. Disorders of the Thyroid Gland. In: Fausi A S, Braunwald E, Kasper D, Hauser S, Longo D, J Jameson et al, editors. Harrison's principles of internal medicine. 17<sup>th</sup> ed. New York: McGraw Hill companies; 2008, p.2229-2233.

2. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. *J Clin Endocrinol Metab.* 2002; 87:1996-2000.
3. Maratou E, Hadjidakis D, Kollias A, Tsegka K, Peppas M, Alevizaki M, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. *Eur J Endocrinol.* 2009.
4. Instructions for use of TSH ELISA [package insert]. Am Eichenhain 1, 48531 Nordhorn: Labor Diagnostika Nord GmbH & Co. KG; 2010.
5. Instructions for use of T<sub>3</sub> ELISA [package insert]. Am Eichenhain 1, 48531 Nordhorn: Labor Diagnostika Nord GmbH & Co. KG; 2010.
6. Instructions for use of T<sub>4</sub> ELISA [package insert]. Am Eichenhain 1, 48531 Nordhorn: Labor Diagnostika Nord GmbH & Co. KG; 2010.
7. Instructions for use of INSULIN ELISA [package insert]. Am Eichenhain 1, 48531 Nordhorn: Labor Diagnostika Nord GmbH & Co. KG; 2009.
8. Trinder P., *Ann. Clin. Biochem.* 1969; 6:24-27.
9. Nader Rifai, G. Russell Warnick. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: Carl Burtis, Edward RA, David EB, editors. *Tietz textbook of clinical chemistry and molecular diagnostics*, 4<sup>th</sup> ed.; New Delhi: Elsevier; 2008, p.903-982.
10. Allain CC, Poon LS, Chan CSG, Richmond W, Fu P. *Clin. Chem.* 1974; 20:470-475.
11. Roeschlau P, Bernt E, Gruber WA. *Clin. Chem. Clin. Biochem.* 1974; 12:226.
12. HOMA calculator [internet]. 2004 [cited 2004]. Available from: <http://www.dtu.ox.ac.uk/homacalculator/index.php>
13. Serter R, Demirbas B, Culha C, Cakal E. The effect of L-thyroxine replacement therapy on lipid based cardiovascular risk in sub clinical hypothyroidism. *Invest J Endocrinol* 2004; 27:897-903.
14. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. *Endocr Pract.* 2002; 8: 457-69.
15. Tuzcu A, Bahceci M, Gokalp D, Tuzun Y, Gunes K. Subclinical hypothyroidism may be associated with elevated high-sensitive c-reactive protein (low grade inflammation) and fasting hyperinsulinemia. *Endocr. J.* 2005 Feb; 52 (1):89-94.
16. Annemieke R, Stephan JL, Links Thera P, Gans Rijk OB, Wolffenbuttel Bruce HR. Thyroid Function is associated with components of the metabolic syndrome in euthyroid subjects. *J Clin Endocrinol Metab* 2007; 92:491-6.
17. Owecki M, El Ali Z, Nikisch E, Sowinski J. Serum insulin levels and the degree of thyroid dysfunction in hypothyroid women. *Neuro Endocrinol Lett* 2008; 29(1):137-40.
18. Reaven GM, Banting lecture. Role of insulin resistance in human disease. *Diabetes* 1988; 37:1595-607
19. Perros P, McCrimmon R, Shaw G, Frier B. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. *Diabet. Med.* 1995; 7:622-7.
20. Dessein PH, Joffe BI, Stanwix AE. Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. *Thyroid.* 2004 Jun; 14 (6):443-6.
21. Eirini Maratou, Dimitrios J Hadjidakis, Anastasios Kollias et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. *European Journal of Endocrinology.* 2009; 160:785–790.
22. Amati F, Dubé JJ, Stefanovic-Racic M, Toledo FG, Goodpaster BH. Improvements in insulin sensitivity are blunted by subclinical hypothyroidism. *Med Sci Sports Exerc.* 2009 February; 41(2):265-9.
23. Singh BM, Goswami B, Mallika V. Association between insulin resistance and hypothyroidism in females attending a tertiary care hospital. *Indian Journal of Clinical Biochemistry.* 2010; 25(2):141-145.
24. Bakker SJL, Ter Maaten JC, Popp-Snijders C, Slaets JPI, Heine RJ, Gans ROB. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. *J Clin Endocrinol Metab* 2001; 86:1206-11.
25. Al Sayed A, Al Ali N, Bo Abbas Y, Alfadhli E. Subclinical hypothyroidism is associated with early insulin resistance in Kuwaiti women. *Endocr J.* 2006 Oct; 53(5):653-7. Epub 2006 Aug 11.
26. Owecki M, Nikisch E, Sowinski J. Hypothyroidism has no impact on insulin sensitivity assessed with homa-ir in totally thyroidectomized patients. *Acta Clin Belg.* 2006 Mar-Apr; 61(2):69-73.
27. Viguerie N, Millet I, Avizou S et al. regulation of human adipocyte gene expression by thyroid hormone. *J Clin Endocrinol Metab* 2002; 87:630-4.
28. Weinstein SP, O'Boyle E, Haber RS. Thyroid hormone increases basal & insulin stimulated glucose transport in skeletal muscle: The role of GLUT-4 glucose transporter expression. *Diabetes.* 1994 Oct; 43(10):1185-1189.
29. George Eimitriadis, Panayota Mitrou, Vaia Lambadiari. Insulin action in Adipose tissue and muscle in hypothyroidism. *Journal of Clinical Endocrinology & Metabolism.* 91(12):4930-4937.
30. Moeller IC, Dumitrescu AM, Walker rl et al. Thyroid hormone responsive genes in cultured human fibroblasts. *J Clin Endocrinol Metab* 2005; 90:936-43.
31. Rochon C, Tauveron I, Dejoux C et al. response of glucose disposal to hyperinsulinemia in human hypothyroidism and hyperthyroidism. *Clin Sci* 2003; 104:7-15.
32. Dimitriadis G, Mitrou P, lambadiari V et al. Insulin action in adipose tissue and muscle in hypothyroidism. *J Clin Endocrinol Metab* 2006; 91: 4930-7.
33. Brenta G, Celi FS, Pisarev M et al. Acute thyroid hormone withdrawal in athyreotic patients results

- in a state of insulin resistance. *Thyroid* 2009; 19: 665-9.
34. Patricia Wu, *Thyroid Disease and Diabetes clinical diabetes.* 18(1).
35. Duntas LH. *Thyroid disease and lipids.* *Thyroid* 2002; 12:287-93.
36. Squizzato A, Gerdes VEA, Brandjes DPM, Büller HR, Stam J. *Thyroid Diseases and Cerebrovascular Disease.* *Stroke.* 2005; 36:2302-2310.
37. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan, diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. *Biochem J.* 1964; 93:652-665.
38. Gerald I. Shulman. Cellular mechanisms of insulin resistance. *Journal of Clinical Investigation.* 106(2): 171-176.

DOI: 10.18203/2320-6012.ijrms20150159

**Cite this article as:** Adhau SR, Girish S, Kansara GS. Insulin resistance in sub clinical hypothyroidism. *Int J Res Med Sci* 2015;3:1420-5.